Novartis AG-RegNVSEF
13F holders, Q3 2025 (September 30)4holders
1new positions
1sold out
$125.81avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding Novartis AG-Reg (NVSEF) in their 13F filings, unchanged from Q2 2025. 1 opened new positions and 1 sold out. The largest holders were Boston Common Asset Management, LLC ($16.2M), Partners Capital Investment Group, LLP ($5.3M) and Generali Investments CEE, investicni spolecnost, a.s. ($2.3M).
- Company
- Novartis AG-Reg
- CUSIP
- H5820Q150
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $70K |
| Exits | 1 | $5.0M |
All 13F filers, Q2 2025 → Q3 2025: 560 shares bought and 67,690 shares sold, net −67,130 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Boston Common Asset Management, LLC | 0.45% | Reduce -16.1% | 129,013 | $16.2M |
| Partners Capital Investment Group, LLP | 0.21% | No change | 42,461 | $5.3M |
| Generali Investments CEE, investicni spolecnost, a.s. | 0.17% | Reduce -6.3% | 18,053 | $2.3M |
| Saranac Partners Ltd | 0.01% | New | 560 | $70K |
"% of holder's portfolio" is NVSEF's weight in each manager's 13F, not the share of Novartis AG-Reg the manager owns.